Efforts to develop neuroprotective therapy for Parkinson disease (PD) are focusing on the
early stages of disease, which offer the best opportunity to intervene. Early PD can be …

Background Given the relative importance of cognitive impairment, there was considerable
interest in identifying the cognitive profile of PD patients, in order to ensure specific and …

Parkinson's disease is the second most common degenerative disease caused by loss of
dopamine producing neurons. The substantia nigra region is deprived of its neuronal …

Introduction: The effects of sodium-glucose cotransporter 2 inhibitors (SGLT2I) and
dipeptidyl peptidase-4 inhibitors (DPP4I) on new-onset cognitive dysfunction in type 2 …

Parkinson's disease (PD) is the second-leading cause of dementia and is characterized by a
progressive loss of dopaminergic neurons in the substantia nigra alongside the presence of …

Background: Changes in communicative functions are common in Parkinson's disease (PD),
but there are only limited data provided by individuals with PD on how these changes are …

Objective To systematically review and meta-analyse conversion rates from normal
cognition to Mild Cognitive Impairment (MCI) and dementia in Parkinson's disease (PD) …

Parkinson's disease (PD) is one of the main types of neurological disorders affected by
progressive brain degeneration. Early detection and prior care may help patients to improve …

REM sleep without atonia (RSWA) is the polysomnographic (PSG) hallmark of rapid eye
movement (REM) sleep behavior disorder (RBD), a feature essential for the diagnosis of this …

Parkinson's disease (PD) is the second most common neurodegenerative disease after
Alzheimer's disease, and its incidence is predicted to increase worldwide. Striatal dopamine …